Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment. PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.

Detailed Description
-----------------
OBJECTIVES: To determine whether single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters are associated with the development and/or severity of mucositis in patients with multiple myeloma receiving high-dose melphalan. To determine whether SNPs in genes that influence melphalan metabolism are associated with the development and/or severity of mucositis in these patients. OUTLINE: This is a multicenter study. Blood or mouthwash samples are collected and DNA isolated from these specimens is analyzed for single nucleotide polymorphisms (SNPs) in LAT1 or other candidate genes. Public databases (i.e., dbSNP and HapMap) are reviewed to select representative SNPs for genotype analysis.

Official Title
-----------------
Genetic Analysis of Toxicity Associated With High-Dose Melphalan

Conditions
-----------------
Mucositis, Multiple Myeloma and Plasma Cell Neoplasm

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of multiple myeloma Receiving treatment with high-dose melphalan for an autologous stem cell transplantation at any of these facilities: Vanderbilt University Medical Center Nashville Veteran's Administration Medical Center (VAMC) Seattle VAMC San Antonio VAMC PATIENT CHARACTERISTICS: Not pregnant PRIOR CONCURRENT THERAPY: See Disease Characteristics No palifermin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective sample<br>People who have been diagnosed with multiple myeloma and have received high-dose melphalan. | Other: laboratory biomarker analysis<br>* Blood or cheek cells wil be collected.<br>|
| Prospective sample<br>People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan. | Other: laboratory biomarker analysis<br>* Blood or cheek cells wil be collected.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters and development and/or severity of mucositis |  | 4 weeks | 
| Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mucositis, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, refractory multiple myeloma